The Role of Serum CD26 in the Diagnosis of Gastric Cancer

Purpose: The value of serum cluster of differentiation 26 (CD26) in gastric cancer remains unknown. We investigated serum CD26 as a non-invasive serological marker for the diagnosis of gastric cancer and its relationship with serum human epidermal growth factor receptor-2 (HER2) levels.Patients and Methods: We enrolled 393 gastric cancer patients treated with endoscopic resection or surgery, and 90 healthy controls. HER2 positivity in tissue was evaluated by immunohistochemistry staining, and the serum CD26 and HER2 levels were measured using an enzyme-linked immunosorbent assay.Results: Serum CD26 levels were significantly lower in gastric cancer patients than in healthy controls (582.2 +/- 254.3 vs 862.7 +/- 410.6 ng/mL, P<0.001). Serum CD26 levels were significantly lower in advanced gastric cancer compared to early gastric cancer (642.2 +/- 333.9 vs 503.4 +/- 332.7 ng/mL, P<0.001), and tended to decrease with gastric cancer progression. To diagnose gastric cancer, the optimal cut-off value of serum CD26 was 762.7 ng/mL with 75.6% sensitivity and 64.4% specificity. Serum CD26 levels were weakly correlated with serum HER2 levels (rs=0.363, P<0.001). However, no difference in serum CD26 levels was observed between tissue HER2-negative and HER2-positive gastric cancer groups (586.2 +/- 362.1 vs 579.6 +/- 264.8 ng/mL, P=0.898).Conclusion: CD26 is a useful non-invasive serological marker for gastric cancer diagnosis; however, its levels do not correlate with HER2 status.

Automated summary

In this study, the value of serum CD26 in gastric cancer and its relationship with serum HER2 levels were investigated. The results showed that serum CD26 levels were significantly lower in gastric cancer patients compared to healthy controls, and they tended to decrease with gastric cancer progression. Serum CD26 was found to be useful for diagnosing gastric cancer, but its levels did not correlate with HER2 status.